Using the huCD20-EL4 tumor model, a murine T-cell lymphoma transfected with the human CD20 molecule, Abes and Xuan reported that by the CD4+, but not CD8+, T-cell immune responses may contribute to long-lasting protection by anti-human CD20 treatment (Abes et al.2010; Xuan et al.2010). Here, CD8A is linked to neoplasm.